Identification of a glycogen synthase kinase-3β inhibitor that attenuates hyperactivity in CLOCK mutant mice

ChemMedChem

Volumn 6, Issue 9, 2011, Pages 1593-1602

  Kozikowski, Alan P ^a   Gunosewoyo, Hendra ^a   Guo, Songpo ^a   Gaisina, Irina N ^a   Walter, Richard L ^a   Ketcherside, Ariel ^b   McClung, Colleen A ^b   Mesecar, Andrew D ^c   Caldarone, Barbara ^d  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c PURDUE UNIVERSITY   (United States)

^d PSYCHOGENICS INC   (United States)

Author keywords

Antimanic agents; Bipolar disorder; Circadian rhythms; CLOCK mutant mice; GSK 3 inhibitors

Indexed keywords

3 (5 FLUORO 1 PIPERIDIN 4 YL 1H INDOL 3 YL) 4 (7 METHOXY BENZOFURAN 3 YL)PYRROLE 2,5 DIONE; 3 (6 METHOXY BENZOFURAN 3 YL) 4 (1 PIPERIDIN 4 YL 1H INDOL 3 YL)PYRROLE 2,5 DIONE; 3 (7 METHOXY BENZOFURAN 3 YL) 4 (1 PIPERIDIN 4 YL 1H INDOL 3 YL)PYRROLE 2,5 DIONE; 3 BENZOFURAN 3 YL 4 (1 PIPERIDIN 4 YL 1H INDOL 3 YL)PYRROLE 2,5 DIONE; 3 BENZOFURAN 3 YL 4 (5 BROMO 1 PIPERIDIN 4 YL 1H INDOL 3 YL)PYRROLE 2,5 DIONE; 3 BENZOFURAN 3 YL 4 (5 CHLORO 1 PIPERIDIN 4 YL 1H INDOL 3 YL)PYRROLE 2,5 DIONE; 3 BENZOFURAN 3 YL 4 (5 FLUORO 1 PIPERIDIN 4 YL 1H INDOL 3 YL)PYRROLE 2,5 DIONE; 3 BENZOFURAN 3 YL 4 [1 (1 METHYL PIPERIDIN 4 YL) 1H INDOL 3 YL]PYRROLE 2,5 DIONE; 3 BENZOFURAN 3 YL 4 [1 (1 PYRIDIN 2 YLMETHYL PIPERIDIN 4 YL) 1H INDOL 3 YL]PYRROLE 2,5 DIONE; 4 (3 METHOXYOXALYL INDOL 1 YL)PIPERIDINE 1 CARBOXYLIC ACID TERT BUTYLESTER; 4 (5 BROMO 3 METHOXYOXALYL INDOL 1 YL)PIPERIDINE 1 CARBOXYLIC ACID TERT BUTYLESTER; 4 (5 BROMO INDOL 1 YL)PIPERIDINE 1 CARBOXYLIC ACID TERT BUTYLESTER; 4 (5 CHLORO 3 METHOXYOXALYL INDOL 1 YL)PIPERIDINE 1 CARBOXYLIC ACID TERT BUTYLESTER; 4 (5 CHLORO INDOL 1 YL)PIPERIDINE 1 CARBOXYLIC ACID TERT BUTYLESTER; 4 (5 FLUORO 3 ETHOXYOXALYL INDOL 1 YL)PIPERIDINE 1 CARBOXYLIC ACID TERT BUTYLESTER; 4 (5 FLUORO INDOL 1 YL)PIPERIDINE 1 CARBOXYLIC ACID TERT BUTYLESTER; 4 [3 (4 BENZOFURAN 3 YL 2,5 DIOXO 2,5 DIHYDRO 1H PYRROL 3 YL) 5 BROMO INDOL 1 YL]PIPERIDINE 1 CARBOXYLIC ACID TERT BUTYLESTER; 4 [3 (4 BENZOFURAN 3 YL 2,5 DIOXO 2,5 DIHYDRO 1H PYRROL 3 YL) 5 CHLORO INDOL 1 YL]PIPERIDINE 1 CARBOXYLIC ACID TERT BUTYLESTER; 4 [3 (4 BENZOFURAN 3 YL 2,5 DIOXO 2,5 DIHYDRO 1H PYRROL 3 YL) 5 FLUORO INDOL 1 YL]PIPERIDINE 1 CARBOXYLIC ACID TERT BUTYLESTER; 4 [3 (4 BENZOFURAN 3 YL 2,5 DIOXO 2,5 DIHYDRO 1H PYRROL 3 YL)INDOL 1 YL]PIPERIDINE 1 CARBOXYLIC ACID TERT BUTYLESTER; 4 [3 [4 (6 METHOXY BENZOFURAN 3 YL) 2,5 DIOXO 2,5 DIHYDRO 1H PYRROL 3 YL]INDOL 1 YL]PIPERIDINE 1 CARBOXYLIC ACID TERT BUTYLESTER; 4 [3 [4 (7 METHOXY BENZOFURAN 3 YL) 2,5 DIOXO 2,5 DIHYDRO 1H PYRROL 3 YL]INDOL 1 YL]PIPERIDINE 1 CARBOXYLIC ACID TERT BUTYLESTER; 4 INDOL 1 YL PIPERIDINE 1 CARBOXYLIC ACID TERT BUTYLESTER; 6 METHOXY BENZOFURAN 3 YL ACETAMIDE; 7 METHOXY BENZOFURAN 3 YL ACETAMIDE; BENZOFURAN 3 YL ACETAMIDE; GLYCOGEN SYNTHASE KINASE 3BETA; PROTEIN SERINE THREONINE KINASE INHIBITOR; TRANSCRIPTION FACTOR CLOCK; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENUATION; CARBON NUCLEAR MAGNETIC RESONANCE; CONTROLLED STUDY; DRUG DESIGN; DRUG IDENTIFICATION; DRUG SOLUBILITY; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPERACTIVITY; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; STRUCTURE ACTIVITY RELATION; THIN LAYER CHROMATOGRAPHY;

ANIMALS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CIRCADIAN RHYTHM; CLOCK PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; GLYCOGEN SYNTHASE KINASE 3; MALE; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; MOTOR ACTIVITY; STRUCTURE-ACTIVITY RELATIONSHIP; TIME FACTORS;

EID: 80052087676     PISSN: 18607179     EISSN: 18607187     Source Type: Journal    
DOI: 10.1002/cmdc.201100188     Document Type: Article

References (29)

1. N. Embi, D. B. Rylatt, P. Cohen, Eur. J. Biochem. 1980, 107, 519.
2. B. W. Doble, J. R. Woodgett, J. Cell Sci. 2003, 116, 1175.
3. H. Eldar-Finkelman, Trends Mol. Med. 2002, 8, 126.
4. R. V. Bhat, J. Shanley, M. P. Correll, W. E. Fieles, R. A. Keith, C. W. Scott, C.-M. Lee, Proc. Natl. Acad. Sci. USA 2000, 97, 11074.
5. C. L. Sayas, A. Ariaens, B. Ponsioen, W. H. Moolenaar, Mol. Biol. Cell 2006, 17, 1834.
6. P. S. Klein, D. A. Melton, Proc. Natl. Acad. Sci. USA 1996, 93, 8455.
7. V. Stambolic, L. Ruel, J. R. Woodgett, Curr. Biol. 1996, 6, 1664.
8. T. D. Gould, H. K. Manji, Neuroscientist 2002, 8, 497.
9. R. Bhat, Y. Xue, S. Berg, S. Hellberg, M. Ormoe, Y. Nilsson, A.-C. Radesaeter, E. Jerning, P.-O. Markgren, T. Borgegard, M. Nyloef, A. Gimenez-Cassina, F. Hernandez, J. J. Lucas, J. Diaz-Nido, J. Avila, J. Biol. Chem. 2003, 278, 45937.
10. K. P. Hoeflich, J. Luo, E. A. Ruble, M.-S. Tsao, O. Jin, J. R. Woodgett, Nature 2000, 406, 86.
11. W. T. O'Brien, A. D. Harper, F. Jové, J. R. Woodgett, S. Maretto, S. Piccolo, P. S. Klein, J. Neurosci. 2004, 24, 6791.
12. J.-M. Beaulieu, T. D. Sotnikova, W.-D. Yao, L. Kockeritz, J. R. Woodgett, R. R. Gainetdinov, M. G. Caron, Proc. Natl. Acad. Sci. USA 2004, 101, 5099.
13. G. Chen, L.-D. Huang, Y.-M. Jiang, H. K. Manji, J. Neurochem. 1999, 72, 1327.
14. C. J. Phiel, F. Zhang, E. Y. Huang, M. G. Guenther, M. A. Lazar, P. S. Klein, J. Biol. Chem. 2001, 276, 36734.
15. X. Li, W. Zhu, M.-S. Roh, A. B. Friedman, K. Rosborough, R. S. Jope, Neuropsychopharmacology 2004, 29, 1426.
16. T. Fukumoto, S. Morinobu, Y. Okamoto, A. Kagaya, S. Yamawaki, Psychopharmacology 2001, 158, 100.
17. L. Chen, G. D. Salinas, X. Li, Mol. Pharmacol. 2009, 76, 1150.
18. J. S. Miller, R. J. Tallarida, E. M. Unterwald, Brain Res. Bull. 2010, 82, 184.
19. P. Cohen, M. Goedert, Nat. Rev. Drug Discovery 2004, 3, 479.
20. E.-M. Hur, F.-Q. Zhou, Nat. Rev. Neurosci. 2010, 11, 539.
21. R. M. Kypta, Expert Opin. Ther. Pat. 2005, 15, 1315.
22. A. P. Kozikowski, I. N. Gaisina, H. Yuan, P. A. Petukhov, S. Y. Blond, A. Fedolak, B. Caldarone, P. McGonigle, J. Am. Chem. Soc. 2007, 129, 8328.
23. I. N. Gaisina, F. Gallier, A. V. Ougolkov, K. H. Kim, T. Kurome, S. Guo, D. Holzle, D. N. Luchini, S. Y. Blond, D. D. Billadeau, A. P. Kozikowski, J. Med. Chem. 2009, 52, 1853.
24. A. L. Vale, F. Ratcliffe, Psychopharmacology 1987, 91, 352.
25. T. Hanania, G.M. Dillon, S.A. Malekiani, M.L. Manzano, E. Leahy, Soc. Neurosci. 35th Annual Meeting, (Washington DC, USA), 2005, abstract 108.9.
26. W. Perry, A. Minassian, D. Feifel, D. L. Braff, Biol. Psychiatry 2001, 50, 418.
27. S. A. Brody, M. A. Geyer, C. H. Large, Psychopharmacology 2003, 169, 240.
28. K. Roybal, D. Theobold, A. Graham, J. A. DiNieri, S. J. Russo, V. Krishnan, S. Chakravarty, J. Peevey, N. Oehrlein, S. Birnbaum, M. H. Vitaterna, P. Orsulak, J. S. Takahashi, E. J. Nestler, W. A. Carlezon, Jr., C. A. McClung, Proc. Natl. Acad. Sci. USA 2007, 104, 6406.
29. C. Aubry, A. J. Wilson, D. Emmerson, E. Murphy, Y. YamChan, M. P. Dickens, M. D. García, P. R. Jenkins, S. Mahale, B. Chaudhuri, Bioorg. Med. Chem. 2009, 17, 6073.